Company: HROW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001641172-25-000925
Chunk: 1093

Company: HARROW, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 6
Chunk 1093
---
 
    $18,829,000  
    $22,781,000  
     41,610,000 
  
    Corporate 

     36,134,000 
  
    Research and development 

     5,045,000 
  
    Income from operations 

    $431,000 

Substantially all revenue is attributable to the
U.S. All long-lived assets at December 31, 2024 and 2023 were located in the U.S.

    F-45

Revenues by segment are further described as follows:

 SCHEDULE
OF REVENUES BY SEGMENT

    For the Years Ended 

    December 31, 

    2024  
    %  
    2023  
    % 
  
    IHEEZO 
    $49,303,000  
     25% 
    $20,621,000  
     16%
  
    VEVYE 
     28,061,000  
     14% 
     1,766,000  
     1%
  
    Other branded products 
     37,836,000  
     19% 
     15,125,000  
     12%
  
    Other revenue, net 
     915,000  
     0% 
     12,746,000  
     10%
  
    Branded revenue, net 
     116,115,000  
     58% 
     50,258,000  
     39%
  
    ImprimisRx revenue, net 
     83,499,000  
     42% 
     79,935,000  
     61%
  
    Total revenues, net 
    $199,614,000  
     100% 
    $130,193,000  
     100%

Other than IHEEZO, VEVYE, and one ImprimisRx product,
no other products accounted for more than 10% of total revenues for the periods presented.

Customer and Supplier Concentrations

Substantially all of the Company’s Branded
sales are made to third-party distributors who sell the products to pharmacies and to the end-users. There were two customers who
comprised more than 10%
of the Company’s Branded revenues for the year ended December 31, 2024 and one customer